ArticleBreast cancer research : BCR2021

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.

Joseph P Garay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.